Scientists have made monumental strides in their quest to protect vulnerable babies from respiratory syncytial virus (RSV): ...
The journey toward an RSV vaccine for children has been wrought with tragedy and setbacks. But six decades after scientists embarked on that path, they are nearing the finish line ...
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi has launched a Phase 1 clinical study titled ‘A Phase 1, Parallel, ...
At first, Ethel Branch thought her two-year-old son, Patro, had a cold or maybe the flu. Frantic, Branch rushed Patro to the ...
With no specific treatment and only partial natural immunity, experts emphasised proactive prevention through hygiene and new ...
“You take the virus, grow it up, purify it and kill it with an inactivating agent. That’s a whole-killed viral vaccine,” said Dr. Paul Offit, director of the Vaccine Education Center at the Children’s ...
Death rates among hospitalized patients were 8.9% to 10.4%, and annual adjusted costs were $32 million to $90 million, mainly ...
Children under 2 years of age are at highest risk for getting critically ill from the flu or RSV and requiring intensive care. Currently, doctors can only provide breathing support for severe flu or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback